The Grants team at Myriad Associates are proud to announce that they have secured over €30m from the Disruptive Technologies Innovation Fund (DTIF) for five, round 3 health and life science projects.
2nd October, 2019
Up to £5 million of funding is available from the Department for International Development (DFID) and the Global Challenges Research Fund (GCRF).
27th September, 2019
Innovate UK will invest up to £25 million in the best game-changing or disruptive ideas with a view to commercialisation.
17th May, 2019
UK businesses doing R&D in immersive technology can apply for a share of up to £2 million grant funding alongside private equity investment. The grant funding is from the Industrial Strategy Challenge Fund.
7th May, 2019
Opportunity to apply for a share of up to £25 million to deliver ambitious or disruptive R&D innovations with significant potential for impact on the UK economy.
1st April, 2019
Smart is the new name for Innovate UK’s ‘Open grant funding’ programme.
Innovate UK will invest up to £20 million in the best game-changing or disruptive ideas with a view to commercialisation.
22nd March, 2019
Innovation has been integral to pharma since the beginning. It is based on creating, developing and testing medications, which are absolutely crucial to the continuation of our civilisation.
5 minute read
Onkimmune was founded in 2015 with the goal of developing novel anti-cancer therapies using Natural Killer (NK) cells.
15th February, 2019
The Fast Track to Innovation (FTI) grant is a European funding programme aiming to encourage both investment and participation in research and innovation and reduce the time from idea to market.
25th January, 2019
There are many resources available to help companies prepare grant applications. For anyone looking to apply for an Innovate UK grant from the UK government, we’ve selected 5 resources that will help you.
14th January, 2019
A successful grant application requires a project that satisfies an identifiable, currently unmet need that you are currently developing.